Mayxay Mayfong, Khanthavong Maniphone, Lindegårdh Niklas, Keola Siamphay, Barends Marion, Pongvongsa Tiengkham, Yapom Ratsuda, Annerberg Anna, Phompida Samlane, Phetsouvanh Rattanaxay, White Nicholas J, Newton Paul N
Wellcome Trust-Mahosot Hospital, Oxford Tropical Medicine Research Collaboration, Vientiane, Lao PDR.
Clin Infect Dis. 2004 Oct 15;39(8):1139-47. doi: 10.1086/424512. Epub 2004 Sep 27.
Recent clinical trials in the Lao People's Democratic Republic have demonstrated that chloroquine and sulfadoxine-pyrimethamine, which are national malaria treatment policy, are no longer effective in the treatment of uncomplicated Plasmodium falciparum malaria.
A randomized comparison of 3 oral antimalarial combinations--chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine--with 42-day follow-up period, was conducted among 330 patients with acute uncomplicated falciparum malaria in southern Laos.
The 42-day cure rates, as determined by intention-to-treat analysis and adjusted for reinfection, were 100%, 97%, and 93% for the groups receiving artesunate plus mefloquine, artemether-lumefantrine, and chloroquine plus sulfadoxine-pyrimethamine, respectively. Of 8 patients receiving chloroquine plus sulfadoxine-pyrimethamine who experienced treatment failure, 6 had early treatment failure. The mean parasite clearance time was significantly longer in patients treated with chloroquine plus sulfadoxine-pyrimethamine (2.9 days; 95% confidence interval [CI], 2.8-3.0 days) than in those treated with artesunate plus mefloquine (2.07 days; 95% CI, 2.0-2.1 days; P<.001) and artemether-lumefantrine (2.08 days; 95% CI, 2.0-2.1 days; P<.001). Cure rates with artemether-lumefantrine were high despite low mean daily dietary fat intake (13.8 g; 95% CI, 12.5-15.1 g) and day 7 plasma lumefantrine concentrations (0.47 mu g/mL; 95% CI, 0.38-0.56 mu g/mL).
Oral artesunate plus mefloquine and artemether-lumefantrine are highly effective for the treatment of uncomplicated falciparum malaria in Laos.
老挝人民民主共和国最近的临床试验表明,作为国家疟疾治疗政策的氯喹和磺胺多辛-乙胺嘧啶,对单纯性恶性疟原虫疟疾的治疗已不再有效。
在老挝南部330例急性单纯性恶性疟患者中,对3种口服抗疟药物组合进行了随机比较——氯喹加磺胺多辛-乙胺嘧啶、青蒿琥酯加甲氟喹、蒿甲醚-本芴醇,并进行了42天的随访。
在意向性分析确定并针对再感染进行调整后,接受青蒿琥酯加甲氟喹、蒿甲醚-本芴醇、氯喹加磺胺多辛-乙胺嘧啶治疗的组,其42天治愈率分别为100%、97%和93%。在接受氯喹加磺胺多辛-乙胺嘧啶治疗而出现治疗失败的8例患者中,6例出现早期治疗失败。接受氯喹加磺胺多辛-乙胺嘧啶治疗的患者,其平均疟原虫清除时间(2.9天;95%可信区间[CI],2.8 - 3.0天)显著长于接受青蒿琥酯加甲氟喹治疗的患者(2.07天;95%CI,2.0 - 2.1天;P<0.001)和接受蒿甲醚-本芴醇治疗的患者(2.08天;95%CI,2.0 - 2.1天;P<0.001)。尽管平均每日膳食脂肪摄入量较低(13.8克;95%CI,12.5 - 15.1克)且第7天血浆本芴醇浓度较低(0.47μg/mL;95%CI,0.38 - 0.56μg/mL),蒿甲醚-本芴醇的治愈率仍很高。
口服青蒿琥酯加甲氟喹和蒿甲醚-本芴醇对老挝单纯性恶性疟的治疗非常有效。